Biotech Companies London – Life Sciences, Investment & Property Guide 2026

Biotech companies in London operate within one of Europe's largest life-sciences ecosystems, supported by major universities, NHS teaching hospitals, research institutes, specialist laboratories, venture capital and pharmaceutical companies.

City Hall reported in November 2025 that London was home to more than 2,700 life-sciences companies, while London's life-sciences sector attracted approximately £1.6 billion of venture-capital investment during 2025 up to that point. The capital also hosts three universities ranked among the world's top 15 for health and clinical science and operations from 19 of the world's 20 largest pharmaceutical companies.

For property owners, investors and developers, the growth of biotechnology is also creating demand for laboratories, R&D facilities, offices, innovation campuses and specialist life-sciences real estate. FraserBond.com can assist with commercial property, development opportunities, acquisitions and property finance advisory and arranging across London.

London's Biotech and Life Sciences Sector

Biotechnology is part of London's broader life-sciences industry, which encompasses areas such as:

• Biopharmaceuticals
• Drug discovery
• Cell and gene therapy
• Genomics
• Diagnostics
• Precision medicine
• Medical technology
• Digital health
• AI-assisted drug discovery
• Clinical research
• Advanced therapies

City Hall describes London as a global life-sciences hub supported by universities, research centres, healthcare providers, medical charities, innovative SMEs and major international companies. The sector employed 31,700 people in London in 2021, according to the latest employment figure cited by City Hall, and generated turnover of approximately £10.8 billion.

Major Biotech Clusters in London

London's biotechnology companies are not evenly distributed across the capital. They tend to cluster around universities, hospitals and research institutions.

City Hall identifies major life-sciences districts including:

These clusters provide different combinations of wet-lab space, offices, clinical institutions, universities and investment networks.

Knowledge Quarter – King's Cross and Euston

The Knowledge Quarter around King's Cross, St Pancras, Bloomsbury and Euston is one of London's most important concentrations of research and innovation.

The location benefits from proximity to institutions including University College London, University College London Hospitals and the Francis Crick Institute.

City Hall stated in October 2025 that the Knowledge Quarter employed approximately 60,000 people across its wider innovation ecosystem.

For life-sciences property investors, the district is important because biotech businesses often seek to locate near research institutions rather than choosing premises purely on conventional office-market criteria.

White City Biotech Cluster

White City Innovation District has developed into another major London life-sciences location.

The district benefits particularly from Imperial College London's presence and the surrounding innovation ecosystem.

MedCity's analysis of London's advanced-therapies companies found that approximately 28% were located in White City, compared with 38% in the Knowledge Quarter, illustrating the concentration of specialist businesses in these two districts.

White City can therefore be particularly relevant for:

Biotech Start-ups + University Spin-outs + Laboratory Businesses + Advanced Therapies + Research Companies

For property investors, the important distinction is between conventional offices and laboratory-capable accommodation.

Canary Wharf Life Sciences

Canary Wharf is increasingly developing a life-sciences presence alongside its established financial-services and technology sectors.

MedCity describes Canary Wharf as an emerging life-sciences cluster, albeit with a smaller existing footprint than established districts such as the Knowledge Quarter and White City.

The location is potentially attractive because it combines large commercial buildings, transport connectivity, institutional landlords and proximity to East London's expanding healthcare and research ecosystem.

For commercial-property investors, this represents a different model from university-centred clusters: adapting a major business district to accommodate research-intensive occupiers.

Whitechapel and Barts Life Sciences

Whitechapel provides another important East London life-sciences location.

Barts Life Sciences brings together Barts Health NHS Trust and Queen Mary University of London, creating connections between researchers, healthcare institutions and businesses.

City Hall has also supported the Barts Life Sciences Innovation programme, including £800,000 of UK Shared Prosperity Fund support aimed at enterprises across London with a particular focus on life sciences for the NHS.

The combination of NHS infrastructure and university research can be particularly valuable for companies involved in diagnostics, clinical innovation and healthcare technology.

London Cancer Hub – Sutton

The London Cancer Hub in Sutton represents a different type of life-sciences development opportunity.

Rather than being situated in Central London's dense commercial environment, Sutton provides the potential for a larger specialist research and innovation campus.

For investors and developers, campus environments can require different property strategies involving:

• Laboratory buildings
• Research facilities
• Offices
• Clinical facilities
• Incubator space
• Supporting amenities
• Longer-term development land

This makes life-sciences property significantly different from conventional office investment.

Paddington Life Sciences

Paddington Life Sciences forms another important cluster.

The location benefits from its connections with Imperial College Healthcare NHS Trust and Paddington's strong transport infrastructure.

City Hall specifically identifies Paddington Life Sciences as one of London's principal life-sciences clusters and includes Imperial College Healthcare NHS Trust among organisations involved in London's life-sciences talent initiatives.

Its Central London accessibility can be particularly attractive to companies requiring connections with hospitals, researchers, investors and international markets.

Examples of Biotech Companies in London

London's biotech ecosystem contains businesses ranging from university spin-outs and early-stage ventures to established biotechnology companies.

Examples associated with London's life-sciences ecosystem have included companies working in areas such as:

• Cell and gene therapy
• Oncology
• Genomics
• Diagnostics
• Drug discovery
• Synthetic biology
• Immunology
• AI-assisted therapeutics

Because biotechnology businesses frequently raise capital, merge, relocate or are acquired, investors researching a specific company should confirm its current operating location and corporate status rather than relying on older biotech directories.

This is particularly relevant when assessing a company as a prospective tenant.

Advanced Therapies Companies in London

Advanced therapies are one of London's specialist strengths.

These can include:

Cell Therapy + Gene Therapy + Regenerative Medicine + Engineered Biological Treatments

MedCity's 2025 analysis found advanced-therapy businesses clustering particularly strongly around the Knowledge Quarter and White City, demonstrating the relationship between company formation and nearby academic institutions.

This clustering has important consequences for property demand.

Biotech companies may prioritise proximity to scientists, hospitals and universities even where property costs are higher.

AI and Biotechnology in London

Artificial intelligence is becoming increasingly integrated with London's life-sciences sector.

Applications include:

• Drug discovery
• Molecular modelling
• Diagnostics
• Clinical-data analysis
• Patient stratification
• Biomarker identification
• Genomics

City Hall reported that London life-sciences businesses had raised approximately £567 million in life-sciences AI investment during 2025 up to October, reflecting growing convergence between London's technology and biotechnology sectors.

This convergence can also affect property requirements because some computational biotechnology companies need substantially less wet-laboratory space than experimental biotech businesses.

Biotech Start-ups in London

London provides an environment for biotech start-ups because founders can potentially access:

Universities → Research → Talent → Hospitals → Laboratories → Venture Capital → Pharmaceutical Partners

University spin-outs are particularly important.

Companies can emerge from research undertaken at institutions such as UCL, Imperial College London, King's College London and Queen Mary University of London.

Their property requirements often change rapidly as they progress from research project to funded company.

A start-up might initially require several laboratory benches before eventually seeking an independent R&D facility.

London Biotech Investment

Biotechnology businesses can require substantial amounts of capital before becoming commercially mature.

Fund